In a filing, Eton Pharmaceuticals Inc revealed its Chief Business Officer Krempa David unloaded Company’s shares for reported $0.25 million on Jun 12 ’25. In the deal valued at $14.92 per share,16,977 shares were sold. As a result of this transaction, Krempa David now holds 629,669 shares worth roughly $8.57 million.
Then, Krempa David sold 10,223 shares, generating $150,585 in total proceeds. Upon selling the shares at $14.73, the Chief Business Officer now owns 612,646 shares.
Before that, Krempa David sold 6,800 shares. Eton Pharmaceuticals Inc shares valued at $100,436 were divested by the Chief Business Officer at a price of $14.77 per share. As a result of the transaction, Krempa David now holds 622,869 shares, worth roughly $8.48 million.
H.C. Wainwright reiterated its Eton Pharmaceuticals Inc [ETON] rating to a Buy in a research note published on January 23, 2025; the price target was $33. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering ETON and reiterated its “Buy” recommendation on January 06, 2025.
Price Performance Review of ETON
On Tuesday, Eton Pharmaceuticals Inc [NASDAQ:ETON] saw its stock fall -3.95% to $13.61. Over the last five days, the stock has lost -13.37%. Eton Pharmaceuticals Inc shares have risen nearly 2.18% since the year began. Nevertheless, the stocks have risen 274.93% over the past one year. While a 52-week high of $21.48 was reached on 05/14/25, a 52-week low of $3.18 was recorded on 04/07/25.
Levels Of Support And Resistance For ETON Stock
The 24-hour chart illustrates a support level at 13.35, which if violated will result in even more drops to 13.09. On the upside, there is a resistance level at 14.11. A further resistance level may holdings at 14.61.
The most recent change occurred on May 06, 2024 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
